Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures

PHASE3CompletedINTERVENTIONAL
Enrollment

308

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Partial Epilepsies
Interventions
DRUG

lacosamide

50mg or 100 mg tablets, up to 800 mg/day given twice daily (BID) throughout the trial

Trial Locations (60)

Unknown

Birmingham

Mobile

Phoenix

Little Rock

Los Angeles

San Francisco

Englewood

Fairfield

Bradenton

Jacksonville

Maitland

St. Petersburg

Tallahassee

Tampa

Atlanta

Chicago

Springfield

Indianapolis

Wichita

Lexington

Louisville

Baltimore

Bethesda

Boston

Golden Valley

Saint Cloud

Saint Paul

Chesterfield

Somerset

Albuquerque

Buffalo

New York

Rochester

Syracuse

Asheville

Durham

Greenville

Winston-Salem

Cincinnati

Cleveland

Columbus

Toledo

Tulsa

Medford

Hershey

Philadelphia

Providence

Beaufort

Charleston

Nashville

Dallas

San Antonio

Charlottesville

Newport News

Norfolk

Richmond

Seattle

Morgantown

Marshfield

Milwaukee

All Listed Sponsors
lead

UCB BIOSCIENCES, Inc.

INDUSTRY

NCT00522275 - Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures | Biotech Hunter | Biotech Hunter